Screening of Potential Molecular Targets for Colorectal Cancer Therapy

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2010 Apr 3

PMID 20360909

Citations 8

Authors

Kimi Honma

Ichiro Takemasa

Ryo Matoba

Yusuke Yamamoto

Fumitaka Takeshita

Masaki Mori

Morito Monden

Kenichi Matsubara

Takahiro Ochiya

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is a leading cause of cancer death worldwide. To identify molecular targets for colorectal cancer therapy, we tested small interfering RNAs (siRNAs) against 97 genes whose expression was elevated in human colorectal cancer tissues for the ability to promote apoptosis of human colorectal cancer cells (HT-29 cells). The results indicate that the downregulation of PSMA7 (proteasome subunit, alpha-type, 7) and RAN (ras-related nuclear protein) most efficiently induced apoptosis of HT-29 cells. PSMA7 and RAN were highly expressed in colorectal cancer cell lines compared with normal colon tissues. Furthermore, PSMA7 and RAN were overexpressed in not only colon tumor tissues but also the other tumor tissues. Moreover, in vivo delivery of PSMA7 siRNA and RAN siRNA markedly induced apoptosis in HT-29 xenograft tumors in mice. Thus, silencing of PSMA7 and RAN induces cancer cells to undergo apoptosis, and PSMA7 and RAN might be promising new molecular targets for drug and RNA interference-based therapeutics against colorectal cancer.

Citing Articles

PSMA7 promotes the malignant proliferation of esophageal cancer.

Jiao Q, Wang Y, Zhang A, Liu Q, Zhou Q Heliyon. 2024; 10(1):e23173.

PMID: 38173490 PMC: 10761361. DOI: 10.1016/j.heliyon.2023.e23173.

Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.

Xia S, Ji L, Tang L, Zhang L, Zhang X, Tang Q Dig Dis Sci. 2021; 67(3):880-891.

PMID: 33721161 DOI: 10.1007/s10620-021-06903-9.

Overexpression of PSMA7 predicts poor prognosis in patients with gastric cancer.

Xia S, Tang Q, Wang X, Zhang L, Jia L, Wu D Oncol Lett. 2019; 18(5):5341-5349.

PMID: 31612044 PMC: 6781669. DOI: 10.3892/ol.2019.10879.

[Expression of PSMA 7 and its effect on proliferation, invasion, migration and tumorigenesis of gastric cancer].

Xia S, Zhang L, Cheng F, Feng Z, Lu L Nan Fang Yi Ke Da Xue Xue Bao. 2019; 39(4):387-393.

PMID: 31068280 PMC: 6743988. DOI: 10.12122/j.issn.1673-4254.2019.04.02.

Salivary exosomal PSMA7: a promising biomarker of inflammatory bowel disease.

Zheng X, Chen F, Zhang Q, Liu Y, You P, Sun S Protein Cell. 2017; 8(9):686-695.

PMID: 28523434 PMC: 5563283. DOI: 10.1007/s13238-017-0413-7.

References

Hu X, Chen W, Wang D, Shi Q, Zhang F, Liao Y . The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer. Oncol Rep. 2008; 19(2):441-6. View

Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R . Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene. 2006; 25(37):5145-54. DOI: 10.1038/sj.onc.1209516. View

Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836):494-8. DOI: 10.1038/35078107. View

Wood J, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J . PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000; 60(8):2178-89. View

Cusack Jr J, Liu R, Houston M, Abendroth K, Elliott P, Adams J . Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001; 61(9):3535-40. View

Hoeller D, Dikic I . Targeting the ubiquitin system in cancer therapy. Nature. 2009; 458(7237):438-44. DOI: 10.1038/nature07960. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Gerards W, de Jong W, Boelens W, Bloemendal H . Structure and assembly of the 20S proteasome. Cell Mol Life Sci. 1998; 54(3):253-62. PMC: 11147335. DOI: 10.1007/s000180050147. View

Mellinghoff I . Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?. PLoS Med. 2007; 4(10):1620-2. PMC: 2043015. DOI: 10.1371/journal.pmed.0040321. View

10.

Richardson P, Mitsiades C, Hideshima T, Anderson K . Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005; 4(2):290-6. View

11.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

12.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

13.

Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K . RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 2008; 14(9):939-48. DOI: 10.1038/nm.1858. View

14.

Kuersten S, Ohno M, Mattaj I . Nucleocytoplasmic transport: Ran, beta and beyond. Trends Cell Biol. 2001; 11(12):497-503. DOI: 10.1016/s0962-8924(01)02144-4. View

15.

Frenzel A, Grespi F, Chmelewskij W, Villunger A . Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis. 2009; 14(4):584-96. PMC: 3272401. DOI: 10.1007/s10495-008-0300-z. View

16.

Pemberton L, Paschal B . Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic. 2005; 6(3):187-98. DOI: 10.1111/j.1600-0854.2005.00270.x. View

17.

Baranda J, Williamson S . The new paradigm in the treatment of colorectal cancer: are we hitting the right target?. Expert Opin Investig Drugs. 2007; 16(3):311-24. DOI: 10.1517/13543784.16.3.311. View

18.

Woo I, Jang H, Eun S, Kim H, Ham S, Kim H . Ran suppresses paclitaxel-induced apoptosis in human glioblastoma cells. Apoptosis. 2008; 13(10):1223-31. DOI: 10.1007/s10495-008-0247-0. View

19.

Klasa R, Gillum A, Klem R, Frankel S . Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002; 12(3):193-213. DOI: 10.1089/108729002760220798. View

20.

Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M . Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000; 60(17):4819-24. View